Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis

Free webinar organized by ZEISS.

Pharma Outsourcing – Find the Right Partner (2025)

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

Phase III win for Hansa Biopharma: “We Are Thrilled”

Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Introducing ZEISS arivis Pro 4.2

ZEISS arivis software enhances custom microscopy image analysis.

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

Samuel Lagercrantz: ”Forskare, se upp för rovtidskrifter!”

”Precis som vi alla behöver vara vaksamma i vår vardag på vad som är sant och vad som är falskt, behöver forskare vara vaksamma på vilka tidskrifter de publicer...

Cellavision belönas med näringslivspris

Blodanalysbolaget Cellavision tilldelas Lunds kommuns näringslivspris.

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...

Introducing ZEISS arivis Pro 4.2

Your solution for advanced image analysis and visualization.

Miljonregn över två svenska biotechbolag – utvalda av EU:s innovationsråd

Pixelgen Technologies och Single Technologies, båda Stockholmsbaserade life science-företag, får finansiering från Europeiska innovationsrådet (EIC) på 12,5 mil...

Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?

In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.

AI-företag köper tillgång till vetenskapliga studier – ”Svårt att reagera som forskare”

Stora förlag för vetenskapliga tidskrifter har i miljonaffärer sålt tillgång till studier till techbolag som utvecklar AI-verktyg. Reaktionerna bland svenska fo...

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

The FDA’s new transparency policy (Part 2)

In the second part of our article series on the FDA’s new “radical transparency” initiative, we explore regulatory strategies to navigate the potential impact o...

Johan Pehrson aviserar sin avgång som partiledare och minister

Regeringens utbildningsminister Johan Pehrson (L), med ansvar för forskningsfrågor, lämnar rollen som partiledare för Liberalerna. Han kommer att fortsätta som ...

Hann du läsa det här? Redaktionen tipsar

Missade du vår rapportering om rovtidsskrifter, rankningen av Sveriges främsta forskare eller reportaget från KI:s zebrafiskakvarium? Inför sommarens lata dagar...

Tyska Biontech storsatsar i Storbritannien

Den tyska vaccin- och läkemedelsutvecklaren Biontech ska investera upp till en miljard pund, motsvarande nästan 13 miljarder kronor, på att utveckla sin forskni...

Will the FDA’s new transparency policy extend to medical devices? (Part 1)

In a significant policy shift, the FDA has begun publishing Complete Response Letters (CRLs) for drug and biologic applications that were initially rejected but...

Astra Zeneca pauses multi-million investment in the UK

Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.

FDA’s new CSA guidance: transforming software validation for production and quality systems

FDA’s final guidance on Computer Software Assurance (CSA) for Production and Quality System Software marks a significant modernization of software validation practices.